上海荣泰健康科技股份有限公司 2023 年度审计报告 中国抗体布钱工需填新业路8号UDC时代大量A座5-8层、17层、23型 Floors 5-18, 12 and 23, Block A. UDC Times Rulining No. 8 Kirry Road. Quirgiong Now Gry. Neigghous Tel. 0571-68879999 Fax. 0571-98870000 www.zhcpa.cn 您可使用手机"扫一扫"或进入"注册会计师行业绩一监管平台（http://acc.mof.gov.cn）"进行查期 报告编码:浙24DOEL9XZJ 目 景 | | 页 次 | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 7-18 | | (一) 合并资产负债表 | 7-8 | | (二) 合并利润表 | 9 | | (三) 合并现金流量表 | 10 | | (四) 合并所有者权益变动表 | 11-12 | | (五) 母公司资产负债表 | 13-14 | | (六) 母公司利润表 | 15 | | (七) 母公司现金流量表 | 16 | | (八) 母 ...

www.zhcpa.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 上海荣泰健康科技股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23. Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 上海荣泰健康科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了上海荣泰健康科技股份有限公司(以下简称荣泰健康公司)2023年12月31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 内部控制审计报告 中汇会审[2024]3644号 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是荣泰 健康公司董事会的责任。 二、注册会计师的责任 我们的 ...

证券代码：603579 证券简称：荣泰健康 公告编号：2024-023 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为了提高公司闲置自有资金的使用效率，保护股东利益，上海荣泰健康科 技股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日召开第四届董事会 第十四次会议及第四届监事会第十一次会议，审议通过了《关于公司 2024 年度 使用闲置自有资金购买理财产品的议案》，同意公司及公司全资子公司、控股 子公司在确保不影响公司日常经营的情况下，使用最高额度不超过人民币 9 亿 元的闲置自有资金进行投资理财，在上述额度内可循环滚动使用。本议案尚需 提交股东大会审议。具体事宜如下： 一、本次委托理财概况 （一）投资目的 投资种类：银行理财产品、券商理财产品、信托理财产品、其他类 投资金额：不超过人民币 9 亿元 已履行及拟履行的审议程序：本事项经第四届董事会第十四次会议及第四 届监事会第十一 ...

上海荣泰健康科技股份有限公司 公司 2023 年 12 月 7 日召开第四届董事会第十一次会议，审议通过《关于调 整审计委员会委员的议案》，根据中国证监会最新颁布的《上市公司独立董事管 理办法》第五条"审计委员会成员应当为不在上市公司担任高级管理人员的董事" 的规定，公司对第四届董事会审计委员会委员进行如下调整：公司董事、高级管 理人员张波不再担任审计委员会委员，由公司董事吴小刚担任审计委员会委员， 与谢树志（召集人）、刘林森共同组成公司第四届董事会审计委员会。吴小刚担任 审计委员会委员的任期自董事会审议通过之日起至本届董事会任期届满之日止。 会议届次 召开日期 会议内容 第四届董事会审计 委员会第二次会议 2023-03-27 审议通过《关于公司 2022 年年度报告及报 告摘要的议案》；《关于公司 2022 年度董事 会审计委员会履职情况报告的议案》；《关 于公司 2022 年度内部控制评价报告的议 2023 年，公司董事会审计委员会共召开 4 次会议： | | | 案》；《关于审阅公司 2022 | 年度财务报告的 | | --- | --- | --- | --- | | | | 议案》；《关于公司 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2024-025 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于开展远期结售汇业务和外汇衍生产品业务的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024 年 4 月 15 日，上海荣泰健康科技股份有限公司（以下简称"公司"） 召开第四届董事会第十四次会议、第四届监事会第十一次会议，审议通过了《关 于公司开展远期结售汇业务和外汇衍生产品业务的议案》及《关于开展外汇套期 交易目的：由于公司国际业务的外汇收付金额较大，外汇汇率/利率波动对公 司经营成果可能产生较大影响。为减少外汇汇率/利率波动带来的风险，公司 拟开展远期结售汇、外汇期权产品等业务，以降低外汇汇率/利率波动带来的 风险； 交易品种：外汇汇率，包括但不限于美元、欧元、港币、韩元等币种； 交易工具：远期结售汇业务、外汇衍生产品业务； 交易场所：具有合法经营资格的金融机构； 交易金额：不超 ...

Financial Performance - Revenue for 2023 was 1.855 billion yuan, a decrease of 7.47% compared to the previous year[3] - Net profit attributable to shareholders was 202.71 million yuan, an increase of 23.43% year-on-year[3] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 186.47 million yuan, an increase of 47.78% year-on-year[3] - The company's basic earnings per share were 1.51 yuan, an increase of 22.76% compared to the previous year[4] - The company's weighted average return on equity was 10.50%, an increase of 1.42 percentage points year-on-year[4] - Revenue for Q1 2023 was RMB 385.72 million, Q2 was RMB 504.18 million, Q3 was RMB 408.17 million, and Q4 was RMB 556.95 million[34] - Net profit attributable to shareholders in Q1 2023 was RMB 37.50 million, Q2 was RMB 67.42 million, Q3 was RMB 46.82 million, and Q4 was RMB 50.97 million[34] - Non-recurring gains and losses for 2023 totaled RMB 16.24 million, compared to RMB 38.04 million in 2022 and RMB 101.70 million in 2021[38] - Revenue decreased year-over-year, but profitability and profit margins improved significantly due to favorable exchange rates and lower raw material prices[42] - Company achieved consolidated operating revenue of 1,855,029,390.81 yuan, a year-on-year decrease of 7.47%[101] - Net profit attributable to the parent company was 202,706,851.03 yuan, a year-on-year increase of 23.43%[101] - Manufacturing sector revenue decreased by 7.10% to 1,839,119,919.42 RMB, with a gross margin increase of 4.00 percentage points to 30.63%[107] - Service sector revenue decreased by 8.61% to 6,041,520.32 RMB, with a gross margin increase of 39.14 percentage points to 66.74%[107] - Total revenue decreased by 7.10% to 1,845,161,439.74 RMB, with a gross margin increase of 4.11 percentage points to 30.74%[107] - Massage chair revenue decreased by 5.90% to 1,766,407,013.60 RMB, with a gross margin increase of 4.22 percentage points to 31.12%[107] - Small appliance revenue decreased by 28.22% to 72,109,722.82 RMB, with a gross margin decrease of 2.61 percentage points to 19.07%[107] - Top 5 customers accounted for 44.13% of total annual sales, totaling 818,697,800 RMB[111] - Top 5 suppliers accounted for 24.21% of total annual procurement, totaling 245,178,300 RMB[111] - Merchant service revenue decreased by 69.22% to 1,066,603.99 yuan, accounting for 53.08% of total revenue[121] - Direct material costs for massage chairs decreased by 13.04% to 993,968,434.26 yuan, accounting for 81.69% of total costs[121] - Total costs for massage chairs decreased by 11.33% to 1,216,732,886.15 yuan[121] - Direct material costs for small electrical appliances decreased by 25.62% to 56,421,849.75 yuan, accounting for 96.68% of total costs[121] - Total costs for small electrical appliances decreased by 25.83% to 58,359,840.21 yuan[121] - Accounts receivable increased by 61.29% to 153,334,053.36 yuan, accounting for 4.53% of total assets[128] - Short-term borrowings decreased by 68.39% to 129,132,300.71 yuan, accounting for 3.81% of total assets[128] - Other equity investments increased by 212.74% to 93,508,800.00 yuan, accounting for 2.76% of total assets[128] - Estimated liabilities increased by 95.01% to 71,577,930.47 yuan, accounting for 2.11% of total assets[128] - The company's total assets as of December 31, 2023, were 3.385 billion yuan, with a debt-to-asset ratio of 41.71% and a credit rating of AA-[197] R&D and Innovation - The company completed 15 R&D projects, added 15 invention patents, 67 utility model patents, 11 design patents, and 11 software copyrights[1] - The company's S80 massage chair won the 2023 MUSE Design Gold Award, and the RT7730 massage chair won the 2023 MUSE Design Silver Award[1] - R&D expenses were 80,176,150.48 yuan, a year-on-year decrease of 9.57%[102] - The company has 182 R&D personnel, accounting for 16.61% of the total workforce[113] - The company is focusing on AI technology, health detection management, and voice interaction to drive innovation in massage chair technology and maintain a competitive edge[140] - The company aims to create a full product matrix of massage chairs, including ultra-high-end, mid-to-high-end, light luxury, and simple models, to enhance competitiveness in various market segments[140] - The company plans to acquire health-related companies with AI capabilities to integrate emerging technologies like cloud computing and big data into its products[141] - The company is enhancing its R&D capabilities and production automation to develop new products and expand its customer base both domestically and internationally[139] Overseas Expansion and Market Strategy - The company plans to establish a factory in Thailand, with a memorandum of cooperation signed with Suvarnabhumi Asia Industrial Park[2] - The company's online direct sales revenue on Douyin achieved rapid growth[15] - Overseas markets showed mixed performance: South Korea recovered in the second half, the US saw a slight decline, while Europe, the Middle East, and Southeast Asia remained stable, with Russia showing significant growth[46] - The company adjusted its European and Southeast Asian market teams by splitting them into two independent teams to better meet customer needs and explore market potential[46] - The company has expanded its overseas market, with products sold to the US, EU, South Korea, Southeast Asia, and countries along the Belt and Road[99] - The company plans to expand its overseas market presence by developing potential markets in Southeast Asia and Europe, and selling its own brand massage chairs and small appliances through e-commerce platforms like Amazon[140] - The company is establishing an overseas production base in Thailand's Suvarnabhumi Asia Industrial Park to better respond to global uncertainties and effectively expand its international market[140] - The company's export business involves direct sales to overseas clients, who then determine the brand, sales channels, and pricing for the products[83] Cost Control and Efficiency - The company's logistics cost control was effective, with a significant reduction in cargo damage rates[2] - Direct material costs decreased by 13.87% to 1.051 billion RMB, accounting for 82.38% of total manufacturing costs[44] - Manufacturing expenses decreased by 3.77% to 88.617 million RMB, accounting for 6.95% of total manufacturing costs[44] - The company implemented cost reduction and efficiency improvement measures, including optimizing supply chain management and reducing unnecessary expenses[42] - The company is improving production efficiency and supply chain management to reduce unit costs through economies of scale[142] - Depreciation costs decreased by 69.00% to 26,727.34 yuan, accounting for 1.33% of total costs[121] Cash Flow and Financial Activities - Operating cash flow increased by 45.40% to 344.295 million RMB, while financing cash flow decreased by 327.18% to 426.170 million RMB[58] - Net cash flow from operating activities was 344,294,659.84 yuan, a year-on-year increase of 45.40%[102] - Net cash flow from investing activities was 120,962,648.98 yuan, compared to -225,043,933.29 yuan in the same period last year[104] - Net cash flow from financing activities was -426,170,282.03 yuan, a year-on-year decrease of 327.18%[104] - The company plans to use idle funds to purchase financial products and manage cash from convertible bonds in 2023[165] - The company will engage in forward exchange and foreign exchange derivative business in 2023[165] - The company plans to sign financing agreements with banks and use idle funds for financial product purchases in 2023[174] Product Portfolio and Sales Channels - The company optimized its product portfolio through product innovation and customization to meet the needs of different markets and channels[42] - The company's main products include massage chairs and small massage devices, with massage chairs providing a full-body massage experience through software-controlled hardware, and small devices focusing on specific body parts[63] - The company operates in the domestic market through five sales channels: distribution, direct sales, e-commerce, experience stores, and ODM, while its export business primarily uses FOB terms[75][76] - As a leading domestic and global manufacturer of massage chairs, the company has over 1,000 offline stores in China and a strong presence on major e-commerce platforms like Tmall, JD.com, and Suning[77] - The company employs a brand differentiation strategy, with the "Rongtai" brand targeting mid-to-high-end massage chairs and the "Momoda" brand focusing on entry-level products[77] - The company has established a multi-channel marketing strategy, including shopping malls, chain stores, car 4S stores, e-commerce, and experience stores[97] Industry and Market Trends - The massage equipment industry in China has grown from RMB 55.819 billion in 2014 to RMB 95.119 billion in 2023, with the household sector accounting for 56.77% of the market in 2023[80] - In 2023, the company produced 191,760 massage chairs, a decrease of 5.75% year-over-year, and sold 268,344 units, a decrease of 6.25% year-over-year[86] - The company's sales of small massage devices in 2023 were 335,595 units, a decrease of 33.57% year-over-year, with inventory decreasing by 4.03%[86] - The company's performance is driven by increasing demand for health-related products, aging populations, and younger consumers seeking relief from work-related stress[85] Investments and Subsidiaries - Other equity instrument investments increased by RMB 63.61 million in 2023, reaching RMB 93.51 million at year-end[40] - Transactional financial assets decreased by RMB 37.93 million in 2023, ending at RMB 15.11 million[40] - Other non-current financial assets increased by RMB 4.48 million in 2023, totaling RMB 99.55 million at year-end[40] - Transactional financial liabilities increased by RMB 7.46 million in 2023, reaching RMB 12.08 million[40] - The total impact of financial asset and liability changes on 2023 profits was a loss of RMB 11.05 million[40] - Shanghai Rongtai Health Technology Co., Ltd. invested 138.9966 million RMB in Shanghai Miaoyin Network Technology Co., Ltd., achieving a 100% ownership[132] - The company invested 4,750 million RMB in Shanghai Rongchang Lingsi Commercial Factoring Co., Ltd., holding a 95% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 167.31 million RMB in Shaoxi Network Technology Co., Ltd., with a 75% ownership[132] - The company invested 3.5 million USD in BODYFRIEND, INC., holding a 35% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 90 million RMB in Guangdong Momole Network Technology Co., Ltd., with a 30% ownership before exiting in November 2023[132] - The company invested 1,764.50 million RMB in Guangzhou Jinno Intelligent Equipment Co., Ltd., holding a 20% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 920 million KRW in BAHC CO., LTD., with a 7.7% ownership[132] - The company invested 1,885 million RMB in Jiaxing Ouyuan Motor Co., Ltd., holding a 35% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 532.65 million RMB in Shanghai Rongyi Electric Appliance Co., Ltd., achieving 100% ownership[132] - The company invested 200 million RMB in Guangdong Kaixuan Sports Goods Co., Ltd., with a 10% ownership[132] Corporate Governance and Shareholder Relations - The company's 2023 annual general meeting approved several key resolutions, including the 2022 annual report, financial report, and profit distribution plan[165] - The company's board of directors approved the 2022 annual report, financial report, and profit distribution plan during the fourth meeting[174] - The company will not adjust the conversion price of "Rongtai Convertible Bonds" in 2023[174] - The company's board of directors held 9 meetings in the year, with all directors attending all meetings either in person or via communication methods[177] - The Audit Committee held 4 meetings during the reporting period, reviewing the company's annual report and providing relevant suggestions[178] - The company's cash dividend policy for 2024 includes a distribution of RMB 10.00 per 10 shares and a capital reserve transfer of 3 shares per 10 shares[181] - In 2023, the company repurchased and canceled 1 million restricted shares, accounting for 0.71% of the total share capital, due to unmet performance conditions[183] - The company's 2021 restricted stock incentive plan's second unlocking period did not meet performance conditions, resulting in the cancellation of 1 million shares[183] - The company's 2021 management partner shareholding plan's second vesting period also did not meet performance conditions, with corresponding shares to be sold and proceeds returned to the company[183] - The company's salary policy includes different structures for production and non-production staff, with future adjustments based on Shanghai's average wage and company performance[180] - The company's cash dividend policy is in compliance with the articles of association, with clear standards, complete decision-making procedures, and protection of minority shareholders' rights[182] - The company's board of directors and audit committee have been diligent in their duties, with no instances of directors missing two consecutive meetings[177][178] - The company has a cumulative cash dividend payout ratio of 38.99% over the past three years and plans to maintain a stable dividend policy[190] Environmental and Social Responsibility - The company and its subsidiaries have implemented carbon reduction measures, reducing CO2 emissions by 2,193.29 tons[185] - The company has built a 1.7MWp distributed rooftop photovoltaic project, generating approximately 1.81 million kWh annually and reducing CO2 emissions by 1,491.44 tons[185] - Subsidiary Zhejiang Rongtai has built an 800KWp distributed rooftop photovoltaic project, generating approximately 850,000 kWh annually and reducing CO2 emissions by 701.85 tons[186] - The company has maintained a stable production and operation, with steady output value and profit, and has obtained multiple quality and safety certifications[189] - The company has established a comprehensive training system, including the development of the Rongtai University E-learning platform, to enhance employee skills and knowledge[195] - The company has actively participated in community civilization construction, forming partnerships with multiple local organizations and achieving a satisfaction rate of over 95%[199] - The company has consistently engaged in disaster relief and donation activities, being recognized as an advanced unit for voluntary blood donation for 10 consecutive years[200] Human Resources and Compensation - Total compensation for directors, supervisors, and senior management in 2023 was 9.0656 million yuan[153] - The company has a total of 1,096 employees, with 651 production personnel, 104 sales personnel, 182 technical personnel, 36 financial personnel, and 123 administrative personnel[159] - The company's educational composition includes 26 employees with a master's degree or above, 272 with a bachelor's degree, 291 with an associate degree, and 507 with education below an associate degree[159] - The total hours of outsourced labor were 1.9895 million hours, with a total payment of 57.1434 million yuan[160] - The company distributed cash dividends of 26.25 million yuan in 2016, 39.375 million yuan in 2015, and 26.25 million yuan in 2014[161] Risk Management and Strategic Goals - The company faces risks from a high concentration of revenue from its major client, BODYFRIEND, which accounted for a significant portion of its main business revenue[163] - The company is actively developing new products with ODM partners and expanding its market presence in Europe and America beyond South Korea[163] - The company is implementing multiple measures to address industry competition, focusing on product innovation and maintaining a strong brand image[164] - The company's strategic goal is to become a leading international fashion health appliance service provider by leveraging its existing technological, market, and production advantages[139] - The company is committed to innovation in products, services, and business models to optimize global residents' quality of life and achieve sustainable growth[139] - The company is leveraging capital markets to raise funds for expanding production scale and improving technological innovation[139]

证券代码：603579 证券简称：荣泰健康 公告编号：2024-027 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 股东大会召开日期：2024年5月8日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一) 股东大会类型和届次 2023 年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 公司会议室 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2024 年 5 月 8 日 14 点 00 分 召开地点：上海市青浦区徐泾镇高光路 169 弄虹桥时代广场 6 号楼荣泰大厦 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 8 日 至 2024 年 5 月 8 日 采用上海 ...

上海荣泰健康科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 www.zhcpa.cn 上海荣泰健康科技股份有限公司全体股东: 我们鉴证了后附的上海荣泰健康科技股份有限公司(以下简称荣泰健康公司) 管理层编制的《关于2023年度募集资金存放与使用情况的专项报告》。 目 录 | 页 次 | | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-3 | | 二、上海荣泰健康科技股份有限公司关于 2023 年度募集资金 | | | | | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New Ci ...

上海荣泰健康科技股份有限公司监事会 关于第四届监事会第十一次会议相关事项的意见 三、关于公司 2023年度利润分配的监事会意见 经核查,我们认为:本次制定的公司 2023年度利润分配方案综合考虑了公 司目前实际情况,与公司成长性相匹配,符合相关法律法规及《公司章程》的要 求,我们同意公司 2023年度利润分配的方案。 四、关于提议续聘公司 2024年度审计机构的监事会意见 经核查,我们认为:中汇会计师事务所(特殊普通合伙)依法独立承办注 册会计师业务,具有证券期货相关业务从业资格,具备为上市公司提供审计服务 的经验和能力,能够为公司提供高品质、高附加值的专业服务,我们同意拟继续 聘请中汇会计师事务所(特殊普通合伙)为公司 2024 年度财务报告审计机构和 内部控制审计机构,负责公司 2024年度财务报告审计和内部控制审计。 五、关于公司 2023年度募集资金存放与实际使用情况的专项报告的监事会 意见 经核查,我们认为:公司 2023年度募集资金的存放与使用符合中国证监会、 上海证券交易所关于上市公司募集资金存放和使用的相关规定,符合公司《募集 资金管理办法》的有关规定,不存在募集资金违规存放和使用的情形。 作 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders for Q1 2024 to be between 59.25 million and 64.58 million yuan, an increase of 21.75 million to 27.08 million yuan compared to the same period last year, representing a year-on-year increase of 58.00% to 72.22%[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 57.55 million and 62.89 million yuan, an increase of 31.69 million to 37.02 million yuan compared to the same period last year, representing a year-on-year increase of 122.50% to 143.11%[5]. - The net profit for the same period last year was 37.50 million yuan, and the net profit after deducting non-recurring gains and losses was 25.87 million yuan[6]. Factors Influencing Performance - The company attributes the performance increase to the recovery of consumer demand and the optimization of product structure, as well as the expansion of domestic and international market share[7]. - The company emphasizes that there are no significant uncertainties affecting the accuracy of this performance forecast[8]. Reporting and Disclosure - The forecast data is preliminary and the final financial data will be disclosed in the official Q1 2024 report[9].